Novartis To Spin-Off Sandoz as Stand-Alone, Public Company
My readers may recall that I disclosed (see my post athttps://blog.sstrumello.com/2022/07/novartis-sandoz-is-back-in-insulin.html for details) some information buried in Novartis ' July 20, 2022 quarterly earnings release, when buried on page 21 of the company ' s 64-page Q2& half-year 2022 financial statement, when we finally learned that the company ' s planned insulin biosimilars first announced in late 2018 were still very much in development. In fact, the Gan& Lee-manufactured insulin glargine U-100, insulin aspart U-100 and insulin lispro U-100 bisimilars were indeed still happening and may actual...
Source: Scott's Web Log - August 27, 2022 Category: Endocrinology Tags: 2022 Biosimilar biosimilars Gan & Lee insulin Novartis Sandoz Source Type: blogs
“ Find The Duck ” Blindfolded – A Healthcare Analogy
I saw this video on social media and I couldn’t help but think that this felt like a lot of people in healthcare. Take a look and see if you know what I mean.
Find the duck 🦆 pic.twitter.com/3S9zOzdLnB
— Fifty Shades of Whey (@davenewworld_2) August 18, 2022
While some may think that this is another Fun Friday article, it’s not really a joke. In fact, it’s kind of sad really. When I watched the video, I thought of all the people in healthcare that go around making money regardless of what happens in healthcare. The payers are probably top of my list, but pharma is in there as well. They&#...
Source: EMR and HIPAA - August 19, 2022 Category: Information Technology Authors: John Lynn Tags: C-Suite Leadership Healthcare IT Healthcare Blindfolds Healthcare Incentives Value Based Care Source Type: blogs
Haunted by the Impunity of Rich Business Leaders - Will One Criminal Conviction make a Difference? The Trump Organization Chief Financial Officer Pleads Guilty
(Source: Health Care Renewal)
Source: Health Care Renewal - August 18, 2022 Category: Health Management Tags: Donald Trump HCA health care corruption impunity Purdue Pharma Source Type: blogs
Lilly Pulls the Plug on Mix-and-Inject Glugagon Rescue Kits
For those who didn ' t hear the news when it broke, diaTribe news reported (seehttps://diatribe.org/glucagon-options-expand-lilly-discontinues-emergency-kit for the news) that Lilly announced that the company intends to discontinue manufacturing its traditional Glucagon Emergency Kitshttps://www.lillyglucagon.com/ by the end of 2022. The kits are old-school, mix& inject kits that many patients (and caregivers alike) really despise because they are rather cumbersome and inconvenient to use when time is of the essence. Having an unpopular product works in the absence of competition, but when newer, more convenient produc...
Source: Scott's Web Log - August 17, 2022 Category: Endocrinology Tags: Eli Lilly and Company glucagon PBM rebates Source Type: blogs
Hackers, Breaches And The Value Of Health Data: 2022 E-Book Update
As solutions like remote care are becoming the norm, 3D printing disrupts the normal supply chain and the number of life science studies on tools like artificial intelligence (A.I.) skyrocket, it’s become clear that we are not anticipating the digital health era; we are in the digital health era. This was to come sooner or later, but the pandemic accelerated the process by years.
However, along with the enhanced healthcare landscape that digital health brings along, there is the pressing issue of privacy. To put it bluntly, there is no digital health without sacrificing a part of our privacy. The advanced techno...
Source: The Medical Futurist - August 11, 2022 Category: Information Technology Authors: Pranavsingh Dhunnoo Tags: Covid-19 Digital Health Research E-Patients Future of Medicine Future of Pharma Genomics Health Sensors & Trackers Healthcare Design Healthcare Policy Personalized Medicine Security & Privacy Telemedicine & Smartphones amazon dev Source Type: blogs
The Future of 3D Printing Drugs In Pharmacies Is Closer Than You Think
3D printing drugs is not a fantasy anymore. Unbelievable shapes and any kind of drug can be fabricated with groundbreaking technology. The UK biotech company, FabRx believes it could even appear as a regular technique in hospitals and pharmacies for creating personalised drugs in specific doses within 5-10 years. In February 2022 the company announced they developed a technology allowing them to 3D print tablets in 7-17 seconds, a huge improvement from earlier.
Print out starfish-shaped drugs for your child at home
Somewhere in the 2030s: Annie was called by her daughter’s teacher that she had a high fever...
Source: The Medical Futurist - August 9, 2022 Category: Information Technology Authors: berci.mesko Tags: 3D Printing Future of Medicine Future of Pharma Healthcare Innovation Personalized medicine GC1 pharmacies 3d printed drugs personalized drugs Source Type: blogs
New curcumin myeloma clinical trial
Conclusion: “Curcumin has an efficacy in improving overall remission and decreasing NF-kB, VEGF, TNF-a, and IL-6 levels in myeloma patients.”
And so we have more proof…and this proof comes from actual myeloma patients, not from cells grown in a Petri dish. The evidence is piling up!
I wonder when (or if!) our myeloma luminaries and organisations are going to wake up to the fact that curcumin has a real potential to help us myeloma folks at every stage of this cancer. If I could, I would tell them (the above luminaries and organisations) to ignore the profits and benefits (international conferences held i...
Source: Margaret's Corner - August 5, 2022 Category: Cancer & Oncology Authors: Margaret Tags: Blogroll curcumin myeloma clinical trial Source Type: blogs
Preventive, Proactive, Productive: Digital Care for Managing Cardiovascular Disease (CVD)
The following is a guest article by Subhro Mallik, SVP and Head of Life Sciences business unit at Infosys.
Cardiovascular disease (CVD) claims more lives than any other ailment. In 2019, it accounted for about one-third of total deaths globally. CVD also takes an enormous economic toll – US$ 1 billion per day in the United States alone. What makes it worse is that more than 80 percent of cardiovascular disease is preventable. Patients have the biggest role in CVD prevention, by eliminating as many lifestyle-related risk factors as possible, such as smoking, unhealthy eating, and physical inactivity. But the healthcar...
Source: EMR and HIPAA - August 4, 2022 Category: Information Technology Authors: Guest Author Tags: Ambulatory Healthcare IT Hospital - Health System Telemedicine and Remote Monitoring Cardiovascular Disease CVD Detection Digital Healthcare Infosys Management prevention Subhro Mallik Source Type: blogs
The Next Evolution of Digital Health – Welcome to the ‘Med-averse’
The following is a guest article by Sheetal Chawla, VP and Head of Life Sciences at Capgemini Americas.
The promise of innovation and efficiency in the new era of medicine could change patient experiences forever
The metaverse is one of the biggest technological breakthroughs of the modern era – on par with the invention of the smartphone. One after another, industries have begun assessing how the promise of the metaverse can advance innovations and usher in progress within any given field.
One industry with massive potential is healthcare. The concept of the metaverse – or ‘med-averse’ as some have coined it –...
Source: EMR and HIPAA - August 3, 2022 Category: Information Technology Authors: Guest Author Tags: C-Suite Leadership Healthcare IT Hospital - Health System Telemedicine and Remote Monitoring Capgemini Americas Digital Healthcare Healthcare Accessibility Med-averse Metaverse Patient Support Randomized Clinical Trials Sheetal Chawl Source Type: blogs
Commentators and Journalists Weigh In On Digital Health And Related Privacy, Safety, Social Media And Security Matters. Lots Of Interesting Perspectives - August 2, 2022.
-----This weekly blog is to explore the news around the larger issues around Digital Health, data security, data privacy, AI / ML. technology, social media and related matters.I will also try to highlightADHA Propagandawhen I come upon it.Just so we keep count, the latest Notes from the ADHA Board were dated 6 December, 2018 and we have seen none since! It ’s pretty sad!Note: Appearance here is not to suggest I see any credibility or value in what follows. I will leave it to the reader to decide what is worthwhile and what is not! The point is to let people know what is being said / published that I have come upon....
Source: Australian Health Information Technology - August 2, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
Bonus Features – July 31, 2022 – House passes bill to extend telehealth flexibility to 2024, only 60% of practices hit their 2021 revenue goal, and more
This article will be a weekly roundup of interesting stories, product announcements, new hires, partnerships, research studies, awards, sales, and more. Because there’s so much happening out there in healthcare IT we aren’t able to cover in our full articles, we still want to make sure you’re informed of all the latest news, announcements, and stories happening to help you better do your job.
News
The U.S. House of Representatives passed by a 416-12 vote the Advancing Telehealth Beyond COVID–19 Act of 2021, which would extend the telehealth flexibilities put in place during the public health emergency until the e...
Source: EMR and HIPAA - July 31, 2022 Category: Information Technology Authors: Brian Eastwood Tags: C-Suite Leadership Clinical Health IT Company Healthcare IT Telemedicine and Remote Monitoring AmerisourceBergen ArchWell Health athenahealth Availity Caption Health CHESS Health Clarify Health Digital Diagnostics Faitility Ful Source Type: blogs
Turning PBM " Arbitrage " On Its Head: Bypassing Insurance to Save
The word of the day is " arbitrage " . Officially, Merriam-Webster defines the English language word " arbitrage " this way: " The nearly simultaneous purchase and sale of securities or foreign exchange in different markets in order to profit from price discrepancies " . However, arbitrage does not exclusively apply to securities sold on Wall Street. The term has also been adopted by the Pharmacy Benefit Manager ( " PBM " ) industry. But PBM ' s are not Wall Street investment banks. And that ' s something we all need to realize.The PBM Accountability Project 2021 report " Understanding the Evolving Business Model...
Source: Scott's Web Log - July 25, 2022 Category: Endocrinology Tags: 2022 arbitrage coupon-generating websites apps coupons Medicare PBM Source Type: blogs
Novartis' Sandoz Is Back In The Insulin Biosims Market. Can It Succeed?
Back in December 2018, the Sandoz division of Swiss pharmaceutical giant Novartis announced (see the full announcementHERE) " Sandoz enters into commercialization and supply agreement for insulin biosimilars " . It also revealed that Sandoz had entered a " commercialization and supply agreement with Gan& Lee " which it added was " a leading insulin supplier headquartered in China with more than 20 years ' experience in insulins and production capacity with attractive cost of goods sold (COGS) structures " .Few Americans have ever heard of Gan& Lee, although this year, at the American Diabetes Association ' s 82nd S...
Source: Scott's Web Log - July 22, 2022 Category: Endocrinology Tags: insulin analogs 2022 Biosimilar biosimilars generics insulin analogues Novartis Sandoz Source Type: blogs
CivicaScript Signs Navitus as Partner; Costco Pharmacies Will Sell Civica Insulin Biosims
$30/vial Could Become The New Normal in 2024My readers may recall that on March 3, 2022, I blogged about concurrent press releases from both Civica, Inc. and the JDRF (see my coverageHERE for original news, followed by more detailed analysis on how it was poised to disrupt the PBM kickback schemeHERE) that its CivicaScripts operating unit plans to enter the U.S. market for insulin biosimilars starting first with the basal insulin analogue insulin glargine, followed by biosimilars of lispro and aspart, which is expected to happen in 2024 assuming it encounters no regulatory delays.The original aim of starting with glargine ...
Source: Scott's Web Log - July 19, 2022 Category: Endocrinology Tags: 2022 Biosimilar biosimilars Civica Civica Rx CivicaRx Costco FDA insulin PBM Source Type: blogs
How Happify Health Became Twill: Inside the New Biz Model & What ’s Next
By JESSICA DaMASSA, WTF HEALTH
Mental health digital therapeutics startup Happify Health has spent the past 5 years quietly ‘self-actualizing’ into a brand-new, tech platform company that just launched this week: Twill. This is a big pivot – not just a brand change – and we’ve got co-founder & President Ofer Leidner and newly-hired Chief Operating Officer Megan Callahan (who formerly ran Lyft Health) here to tell us how it all went down AND what will happen to the old Happify app.
Wellness-app-no-more, Twill has emerged as a health tech infrastructure company. Its core product (called Sequences) is the...
Source: The Health Care Blog - July 14, 2022 Category: Consumer Health News Authors: matthew holt Tags: Health Tech Health Technology Jessica DaMassa WTF Health Happify Health Jess DaMassa Megan Callahan Ofer Leidner Twill Source Type: blogs
